pharma · Non-small Cell Lung Cancer · Solid Tumors
BioNTech SE
NovaPharmaNews editorial coverage mentioning BioNTech SE — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- An der Goldgrube 12, Mainz, Rhineland-Palatinate 55131, DE
- Founded
- 2008
- Employees
- 5,119
- Programs
- 23
- Drugs
- 35
- Patents
- 25
News & analysis
NovaPharmaNews articles mentioning BioNTech SE — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning BioNTech SE — regulatory, clinical, and market analysis.
BioNTech and Pfizer's Bispecifics Data: Insights and Implications
BioNTech and Pfizer present promising bispecifics data, while FDA's Pazdur highlights potential opportunities. Discover the implications for the pharma sector.
#ASCO26: Insights on VEGF Bispecifics from BioNTech-BMS and Pfizer-3SBio
This article delves into the new data released at ASCO26 regarding VEGF bispecifics from BioNTech-BMS and Pfizer-3SBio, highlighting implications for the pharmaceutical industry.